SCHEMBL7358290

SCHEMBL7358290

CC(C)c1ncccc1CCl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.33
SLC13A5 Q86YT5 1/20 0.32
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
HTT P42858 3/20 0.32
PDK2 Q15119 1/20 0.32
KMT2A Q03164 2/20 0.32
GRM4 Q14833 2/20 0.32
MAPT P10636 2/20 0.32
CYP1A2 P05177 1/20 0.32
CASP3 P42574 2/20 0.31
SENP8 Q96LD8 2/20 0.31
SENP7 Q9BQF6 2/20 0.31
SENP6 Q9GZR1 2/20 0.31
MEN1 O00255 1/20 0.31
TSHR P16473 1/20 0.31
NPC1 O15118 2/20 0.30
L3MBTL1 Q9Y468 2/20 0.30
KDM1A O60341 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10650516 0.83 KDM4E (0.35) DPP4KDM4EALDH1A1KMT2AMAPT
SCHEMBL18335088 0.82 KDM4E (0.34) DPP4KDM4EKMT2AGRM4MAPT
SCHEMBL1132718 0.81 LMNA (0.39) KDM4EALDH1A1GRM4MAPTCYP1A2
SCHEMBL30567627 0.81 CYP11B1 (0.33) KDM4EHTTPDK2KMT2AMAPT
SCHEMBL11261342 0.80 GABRA1 (0.32) KDM4EKMT2AMAPTMEN1TSHR
SCHEMBL14485138 0.79 GABRA1 (0.47) KDM4EALDH1A1HTTPDK2MAPT
SCHEMBL13772949 0.79 DPP4 (0.43) DPP4KDM4EPDK2MAPTCYP1A2
SCHEMBL5109205 0.79 MEN1 (0.45) KDM4EALDH1A1HTTPDK2KMT2A
SCHEMBL23641297 0.78 GRM5 (0.44) KDM4EALDH1A1L3MBTL1
SCHEMBL23075001 0.76 SLC6A2 (0.41) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed
US-5726172-A BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA MERCK & CO., INC. (US) 1998-03-10 US disclosed
WO-1997025992-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN DPP4 1307/4885SLC13A5 709/4885KDM4E 3899/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN DPP4 1307/4885SLC13A5 709/4885KDM4E 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.